A difficult first half
Judges Scientific plc (LSE:JDG), the acquirer and operator of scientific instrument businesses, reported a sharp fall in first-half profits on 23 September 2026 but maintained its guidance for the full year. Revenue for the six months to 30 June 2026 fell 21% to £55.7m from £70.2m, and adjusted pre-tax profit dropped 75% to £3.2m from £12.6m. Chair David Cicurel described it as a very poor first half performance. Despite this, the board raised the interim dividend and said full-year expectations remained in line with consensus.
What the company does
Judges Scientific buys and grows small and medium-sized businesses that design and manufacture scientific instruments. Its companies serve customers in academic laboratories, industry and other specialist markets worldwide. The group's strategy is to acquire niche businesses with leading positions in their fields and hold them for the long term, using cash generation to fund further acquisitions and dividends.
Latest developments
Order intake in the first half was down 12% year on year, and the order book stood at 17.3 weeks, broadly unchanged from 17.4 weeks a year earlier. The company noted that eight of its businesses grew in the period. Encouragingly, order intake in the second half was about 1% behind the prior year at the date of the report, a marked improvement on the first half. The board maintained 2026 guidance in line with consensus adjusted earnings per share of 200.5p.
There have also been leadership changes. Chief financial officer Brad Ormsby intends to step down and will remain for up to twelve months, according to a board change announcement on the same day. Earlier, in February 2026, Tim Prestidge became chief executive and David Cicurel moved to non-executive chair. Directors have reported several share dealings during 2026, most recently on 6 October.
Financial and dividend picture
Adjusted basic earnings per share fell to 39.0p from 141.4p, and on a statutory basis the group recorded a pre-tax loss of £1.7m, compared with a profit of £6.6m. Cash generated from operations fell to £4.3m from £12.3m. Adjusted net debt rose to £45.3m from £42.6m at the end of 2025, and gearing increased to 2.1 times from 1.5 times. After the period end, banking facilities were extended to 1 July 2030. The interim dividend was raised 10% to 36.0p, with an ex-dividend date of 8 October 2026 and payment due on 6 November 2026.
Sector and index context
Demand for scientific instruments depends on laboratory budgets, industrial investment and export markets, all of which can be affected by funding cycles and trade conditions. Within the FTSE AIM All Share Index, Judges Scientific is an acquisitive industrial group whose buy-and-build model depends on steady cash generation, so a weak half draws particular attention from investors.
Key risks
Meeting full-year guidance requires a much firmer second half, which depends on order intake continuing to recover. Higher gearing reduces flexibility for acquisitions, and science funding pressures or trade disruption could weigh on demand. Management transitions, with a new chief executive and a departing finance director, also bring execution risk.
What to watch next
Investors will look for a year-end trading update confirming whether the second-half recovery has been delivered against the 200.5p adjusted earnings per share consensus. Trends in order intake, net debt reduction, the appointment of a new chief financial officer and any acquisitions will also be closely watched ahead of full-year results.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...